- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02997137
Impact of an Amino Acid Composition With Micronutrients on Wellbeing of Patients With Chronic Exhaustion Conditions (BOT-01)
Impact of a Specific Amino Acid Composition With Micronutrients on Wellbeing and Endocrine-cardiometabolic Situation of Patients With Chronic Exhaustion Conditions, Such as Burnout
Chronic psychological distress can lead to chronic exhaustion conditions, such as burnout. These conditions are associated with a deficiency of specific amino acids and micronutrients that cause endocrine-cardiometabolic abnormalities. These people have specific medically-determined nutrient requirements.
Aim of this study is to demonstrate, that the daily oral administration of a specific amino acid composition (dosage 4.2 g/day) with micronutrients (e. g. 7 vitamins of the B-complex, magnesium, zinc) designed to decrease chronic exhaustion conditions will significantly decrease the perceived chronic distress and associated chronic exhaustion conditions of women and men after 8 and 12 weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic psychological distress can lead to chronic exhaustion conditions, such as burnout. This clinical condition is characterized by reduced satisfaction in performance, exhaustion and depersonalization. Individuals under prolonged exposure to chronic work-life stress and insufficient recovery are at high risk for developing burnout symptoms. Social services, caregiving and teaching professions with a perceived imbalance of effort and reward are often affected. Until now, a general accepted definition of burnout syndrome and its binding diagnostic criteria have not been established. Moreover, there is a strong association between chronic psychological distress and somatoform symptoms, like sleeping disturbances, headaches and abdominal pain that cannot be fully explained by medical or neurological condition. Physiologically the hypothalamus pituitary adrenal axis (HPA-axis) is the central system for the long term adaptation of an organism to stress. During stress exposure, the HPA-axis is activated and the adrenal cortex produces high levels of cortisol with a stress inhibitory function at the same time. However, exposure to long-term chronic stress is associated with biological dysregulation and can result in hypofunctioning of the HPA-axis and a state of hypocortisolism. In addition, the serotonergic system, the immune system and the amino acid metabolism get adversely affected.
Stress-related eating behaviours frequently results in an imbalance of amino acids and deficiency of micronutrients (i. e. B-vitamins and magnesium) that cause endocrine-cardiometabolic abnormalities. Intake of specific amino acids can affect the brain functioning and mental health. Some amino acids are precursors of the neurotransmitters in the brain. Moreover, l-ornithine and taurine are suggested to have an antifatigue effect. Dietary intake of B-vitamins and magnesium, the important stress-mineral, had positive effects on mood and perceived stress.
Aim of this study is to demonstrate, that the daily oral administration of a specific amino acid composition (dosage 4.2 g/day) with micronutrients (e. g. 7 vitamins of the B-complex, magnesium, zinc) designed to decrease chronic exhaustion conditions will significantly decrease the perceived chronic distress and associated chronic exhaustion conditions of women and men after 8 and 12 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Sigmund-Freud Str. 25
-
Bonn, Sigmund-Freud Str. 25, Germany, 53105
- Department of Urology, University of Bonn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-65 years
- Perceived Stress Questionnaire 30 (PSQ30): total score > 0.50
Exclusion Criteria:
- Age: < 18 and > 65 Years
- Perceived Stress Questionnaire (PSQ30): total score ≤ 0.50
- Supplementation or therapy with dietary supplements or drugs which contains amino acids (e. g. l-tryptophan), vitamins and other micronutrients (have to discontinue 4 weeks prior to the start of the study)
- Therapy with antidepressant drugs such as monoamine oxidase inhibitors
- Hypertension (untreated > 150/90 mmHg, treated > 140/85 mmHg)
- Organic fatigue
- Phenylketonuria
- Acute and chronic diarrhea
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: BOT-01
Dietary supplement: specific amino acid composition with micronutrients
|
Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water. Duration: 12 weeks
Other Names:
|
|
Placebo Comparator: Placebo
Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties
|
Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water. Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties. Duration: 12 weeks |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perceived Stress Questionnaire (PSQ30)
Time Frame: 12-week dietary intervention
|
Intervention changes in the total PSQ30 score at baseline and after 12 weeks
|
12-week dietary intervention
|
|
Perceived Stress Questionnaire (PSQ30)
Time Frame: 8-week dietary intervention
|
Intervention changes in the total PSQ30 score at baseline and after 8 weeks
|
8-week dietary intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Salivary cortisol concentration in the evening (between 10 and 11 pm, at least 30 minutes after dinner) and in the morning (30 minutes after waking in the morning)
Time Frame: 12-week dietary intervention
|
Intervention changes in difference between salivary cortisol concentrations (evening - morning) at baseline and after 12 weeks
|
12-week dietary intervention
|
|
The Visual Analog Scale (VAS)
Time Frame: 12-week dietary intervention
|
Intervention changes in mean VAS score at baseline and after 12 weeks
|
12-week dietary intervention
|
|
The Visual Analog Scale (VAS)
Time Frame: 8-week dietary intervention
|
Intervention changes in mean VAS score at baseline and after 8 weeks
|
8-week dietary intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psychological Neurological Questionnaire (PNF)
Time Frame: 12-week dietary intervention
|
Pre-post intervention changes in total number of points from the PNF and the psycho-neurovegetative stability (PN), a category of the PNF.
|
12-week dietary intervention
|
|
Morning salivary cortisol concentration (30 minutes after waking)
Time Frame: 12-week dietary intervention
|
Pre-post intervention changes in salivary cortisol concentration at baseline and after 12 weeks
|
12-week dietary intervention
|
|
Evening salivary cortisol concentration (between 10 and 11 pm, at least 30 minutes after dinner)
Time Frame: 12-week dietary intervention
|
Pre-post intervention changes in salivary cortisol concentration at baseline and after 12 weeks
|
12-week dietary intervention
|
|
3-day food records
Time Frame: 12-week dietary intervention
|
Pre-post intervention changes in dietary intake at baseline and after 12 weeks
|
12-week dietary intervention
|
|
Endocrine-cardiometabolic parameters (i. e. serotonin, amino acids in the blood)
Time Frame: 12-week dietary intervention
|
Pre-post intervention changes in blood parameters at baseline and after 12 weeks
|
12-week dietary intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kyberg-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychological Distress
-
Universita di VeronaUniversity of Roma La SapienzaRecruitingDistress, Emotional | Distress, PsychologicalItaly
-
Utah State UniversityCompletedPsychological Distress | Psychological Flexibility | Psychological Well-BeingUnited States
-
Universidad de las Americas - QuitoRecruitingPsychological DistressEcuador
-
Barbel KnauperNot yet recruitingPsychological DistressCanada
-
Fondation Santé des Étudiants de FranceRecruitingPsychological DistressFrance
-
Fondazione IRCCS Policlinico San Matteo di PaviaCompletedPsychological DistressItaly
-
Azienda Unita Sanitaria Locale di PiacenzaUniversity of Siena, ItalyCompleted
-
International Islamic University MalaysiaCompletedPsychological DistressSingapore
-
George Washington UniversityWorld Health Organization; Transcultural Psychosocial Organization Nepal; Socios... and other collaboratorsCompletedPsychological DistressNepal, Peru, Uganda
-
University of LincolnLincolnshire Partnership NHS Foundation TrustCompletedPsychological DistressUnited Kingdom
Clinical Trials on BOT-01
-
George Washington UniversityNot yet recruiting
-
University of PennsylvaniaCompleted
-
Institute of Psychology, Chinese Academy of SciencesCompletedDepression | Anxiety | LLM-based AI Dialogue BotChina
-
Universidade do PortoUnidade Local de Saúde de Matosinhos, EPE; Instituto de Saude Publica da Universidade... and other collaboratorsNot yet recruitingCognitive Dysfunction | Mild Cognitive ImpairmentPortugal
-
University of CincinnatiActive, not recruitingPapillomavirus Vaccines | Human Papillomavirus VirusesUnited States
-
Mount Sinai Rehabilitation HospitalCompletedMultiple SclerosisUnited States
-
University Hospital, GhentCompleted
-
Darren Sigal, MDScripps HealthNot yet recruiting
-
Chang Gung University of Science and TechnologyNot yet recruitingStress | Nursing Education | Mental Health
-
Gerencia de Atención Primaria, MadridInstituto de Salud Carlos IIICompletedTobacco Use CessationSpain